<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904057</url>
  </required_header>
  <id_info>
    <org_study_id>P140891</org_study_id>
    <nct_id>NCT02904057</nct_id>
  </id_info>
  <brief_title>Evaluation of the MJGS Following Radiesse (+) Injection Into the Jawline</brief_title>
  <official_title>Evaluation of the Merz Jawline Grading Scale (MJGS) Following Radiesse (+)® Correction of Subcutaneous Volume Loss and Contour Deficits of the Jawline - a Canadian Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the sensitivity of the validated Merz Jawline Grading Scale (MJGS)&#xD;
      to detect treatment effects following Radiesse (+) correction of subcutaneous volume loss and&#xD;
      contour deficits of the jawline. Treatment effects detected on the MJGS will be correlated&#xD;
      with assessments of aesthetic outcomes on the Global Aesthetic Improvement Scale (GAIS) and&#xD;
      FACE-Q instrument&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, open label study, in which both right and left jawlines will receive treatment&#xD;
      with Radiesse (+). Subjects will be randomized in a 2:1 ratio to either a treatment group or&#xD;
      an untreated control group. Jawlines will be assessed by masked evaluators on the MJGS.&#xD;
      Treating physicians and treatment group subjects will assess satisfaction on the GAIS.&#xD;
      Treatment group subjects will self-report aesthetic outcomes on the FACE-Q instrument.&#xD;
&#xD;
      Treatment subjects will be evaluated at enrollment, and 1, 2 and 4 weeks after enrollment.&#xD;
      Control group subjects will be required to be evaluated at enrollment and 4 weeks after&#xD;
      enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Jawlines Achieving Greater Than or Equal to (&gt;=) 1-point Improvement on Merz Jawline Grading Scale (MJGS) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>MJGS is a 5-point scale, where score ranges from (0-4) as, score 0: continuous jawline contour, no downshifting of subcutaneous volume; score 1: mild loss of jawline contour, mild downshifting of subcutaneous volume; score 2: moderate loss of jawline contour, moderate downshifting of subcutaneous volume; score 3: severe loss of jawline contour, severe downshifting of subcutaneous volume and score 4: very severe loss of jawline contour, diffuse mandibular angle, very severe downshifting of subcutaneous volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Group, Radiesse (+) Injectable Implant: Percentage of Jawlines With &gt;=1-point Improvement on the MJGS Versus at Least an Improved Rating on Global Aesthetic Improvement Scale (GAIS) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>MJGS is a 5-point scale, where score ranges from (0-4) as, score 0: continuous jawline contour, no downshifting of subcutaneous volume; score 1: mild loss of jawline contour, mild downshifting of subcutaneous volume; score 2: moderate loss of jawline contour, moderate downshifting of subcutaneous volume; score 3: severe loss of jawline contour, severe downshifting of subcutaneous volume, and; score 4: very severe loss of jawline contour, diffuse mandibular angle, very severe downshifting of subcutaneous volume. The GAIS is a 7-point scale, where score ranges from (0-7) as: score 0: very much worse; score 1: much worse; score 3: worse; score 4: no change; score 5: improved; score 6: much improved; score 7: very much improved. An &quot;improvement&quot; on the GAIS for the treating investigator was classified as investigators who rated participants as &quot;improved&quot;, &quot;much improved&quot;, or &quot;very much improved&quot;. All other ratings on the GAIS were classified as &quot;no improvement&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Volume Loss of the Jawline</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiesse (+) Injectable Implant</intervention_name>
    <description>Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has right and left jawlines with moderate to severe volume/contour loss as determined&#xD;
             by a live, masked evaluator.&#xD;
&#xD;
          2. Is at least 18 years of age.&#xD;
&#xD;
          3. Understands and accepts the obligation not to receive any other procedures below the&#xD;
             orbital rim including the neck during participation in the study.&#xD;
&#xD;
          4. Understands and accepts the obligation and is logistically able to present for all&#xD;
             scheduled study visits and meet all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has ever been treated with silicone, PMMA (polymethyl methacrylate), fat injections,&#xD;
             poly-L-lactic acid (PLLA; Sculptra®) or permanent dermal fillers below the orbital rim&#xD;
             including the neck.&#xD;
&#xD;
          2. Has had surgery on the jawbone or has surgical permanent implant to the face or neck.&#xD;
&#xD;
          3. Has bruxism, masseter muscle hypertrophy or asymmetry of masseter muscles, active&#xD;
             temporomandibular joint (TMJ) disease or disorder, or active periodontal disease.&#xD;
&#xD;
          4. Has any medical condition with the potential to interfere with the study or increase&#xD;
             the risk of adverse events.&#xD;
&#xD;
          5. Has undergone oral surgery recently or plans to undergo oral surgery procedures during&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kuligowski, MD,PHD,MBA</last_name>
    <role>Study Director</role>
    <affiliation>Study Director</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <results_first_submitted>October 20, 2020</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <disposition_first_submitted>June 7, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 7, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2017</disposition_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 2 sites in Canada.</recruitment_details>
      <pre_assignment_details>A total of 29 participants were screened for the study and all 29 participants were enrolled and treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group: Radiesse (+) Injectable Implant</title>
          <description>Participants received Radiesse+Lidocaine Injectable Implant up to 3.0 cubic centimeter (cc) volume, once within the jawline region of anterior to posterior boundaries (from the mentum to the earlobe) and superior to inferior boundaries (from the lower cheek to the lower body of the jawline).</description>
        </group>
        <group group_id="P2">
          <title>Control Group: Untreated</title>
          <description>Participants did not receive jawline treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The randomized set comprised of participants enrolled and randomized into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group: Radiesse (+) Injectable Implant</title>
          <description>Participants received Radiesse+Lidocaine Injectable Implant up to 3.0cc volume, once within the jawline region of anterior to posterior boundaries (from the mentum to the earlobe) and superior to inferior boundaries (from the lower cheek to the lower body of the jawline).</description>
        </group>
        <group group_id="B2">
          <title>Control Group: Untreated</title>
          <description>Participants did not receive jawline treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="7.01"/>
                    <measurement group_id="B2" value="59.2" spread="6.39"/>
                    <measurement group_id="B3" value="57.3" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick skin type</title>
          <description>Fitzpatrick skin type depends on the amount of melanin pigment in the skin. This is determined by constitutional colour (white, brown or black skin) and the result of exposure to ultraviolet radiation (tanning). It depends on type of skin where, skin type I:pale or white skin-always burns, does not tan;skin type II:fair skin-burns easily, tans poorly;skin type III:darker white skin-tans after initial burn;skin type IV:light brown skin-burns minimally, tans easily;skin type V:brown skin-rarely burns, tans darkly easily and skin type VI:dark brown or black skin-never burns, always tans darkly.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Type I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Jawlines Achieving Greater Than or Equal to (&gt;=) 1-point Improvement on Merz Jawline Grading Scale (MJGS) at Week 4</title>
        <description>MJGS is a 5-point scale, where score ranges from (0-4) as, score 0: continuous jawline contour, no downshifting of subcutaneous volume; score 1: mild loss of jawline contour, mild downshifting of subcutaneous volume; score 2: moderate loss of jawline contour, moderate downshifting of subcutaneous volume; score 3: severe loss of jawline contour, severe downshifting of subcutaneous volume and score 4: very severe loss of jawline contour, diffuse mandibular angle, very severe downshifting of subcutaneous volume.</description>
        <time_frame>Week 4</time_frame>
        <population>The full analysis set (FAS) comprised of the subset of participants in the randomized set for whom the primary efficacy variable was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group: Radiesse (+) Injectable Implant</title>
            <description>Participants received Radiesse+Lidocaine Injectable Implant up to 3.0cc volume, once within the jawline region of anterior to posterior boundaries (from the mentum to the earlobe) and superior to inferior boundaries (from the lower cheek to the lower body of the jawline).</description>
          </group>
          <group group_id="O2">
            <title>Control Group: Untreated</title>
            <description>Participants did not receive jawline treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Jawlines Achieving Greater Than or Equal to (&gt;=) 1-point Improvement on Merz Jawline Grading Scale (MJGS) at Week 4</title>
          <description>MJGS is a 5-point scale, where score ranges from (0-4) as, score 0: continuous jawline contour, no downshifting of subcutaneous volume; score 1: mild loss of jawline contour, mild downshifting of subcutaneous volume; score 2: moderate loss of jawline contour, moderate downshifting of subcutaneous volume; score 3: severe loss of jawline contour, severe downshifting of subcutaneous volume and score 4: very severe loss of jawline contour, diffuse mandibular angle, very severe downshifting of subcutaneous volume.</description>
          <population>The full analysis set (FAS) comprised of the subset of participants in the randomized set for whom the primary efficacy variable was available.</population>
          <units>percentage of jawlines</units>
          <param>Number</param>
          <units_analyzed>Jawlines</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Jawlines</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Imputed data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Observed data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Imputed Data: Difference between proportion of treatment responders and control responders (P[treatment] - P[control] with confidence interval (CI) was calculated using an exact approach.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between proportion</param_type>
            <param_value>92.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.4</ci_lower_limit>
            <ci_upper_limit>98.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Observed Data: Difference between proportion of treatment responders and control responders (P[treatment] - P[control] with CI was calculated using an exact approach.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between proportion</param_type>
            <param_value>92.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.4</ci_lower_limit>
            <ci_upper_limit>98.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Group, Radiesse (+) Injectable Implant: Percentage of Jawlines With &gt;=1-point Improvement on the MJGS Versus at Least an Improved Rating on Global Aesthetic Improvement Scale (GAIS) at Week 4</title>
        <description>MJGS is a 5-point scale, where score ranges from (0-4) as, score 0: continuous jawline contour, no downshifting of subcutaneous volume; score 1: mild loss of jawline contour, mild downshifting of subcutaneous volume; score 2: moderate loss of jawline contour, moderate downshifting of subcutaneous volume; score 3: severe loss of jawline contour, severe downshifting of subcutaneous volume, and; score 4: very severe loss of jawline contour, diffuse mandibular angle, very severe downshifting of subcutaneous volume. The GAIS is a 7-point scale, where score ranges from (0-7) as: score 0: very much worse; score 1: much worse; score 3: worse; score 4: no change; score 5: improved; score 6: much improved; score 7: very much improved. An &quot;improvement&quot; on the GAIS for the treating investigator was classified as investigators who rated participants as &quot;improved&quot;, &quot;much improved&quot;, or &quot;very much improved&quot;. All other ratings on the GAIS were classified as &quot;no improvement&quot;.</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS comprised the subset of participants in the randomized set for whom the primary efficacy variable was available. The GAIS was assessed only in treated subjects (i.e., not in Control Group: Untreated); therefore, the analysis is on observed cases, where data were available for both assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group: Radiesse (+) Injectable Implant</title>
            <description>Participants received Radiesse+Lidocaine Injectable Implant up to 3.0cc volume, once within the jawline region of anterior to posterior boundaries (from the mentum to the earlobe) and superior to inferior boundaries (from the lower cheek to the lower body of the jawline).</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Group, Radiesse (+) Injectable Implant: Percentage of Jawlines With &gt;=1-point Improvement on the MJGS Versus at Least an Improved Rating on Global Aesthetic Improvement Scale (GAIS) at Week 4</title>
          <description>MJGS is a 5-point scale, where score ranges from (0-4) as, score 0: continuous jawline contour, no downshifting of subcutaneous volume; score 1: mild loss of jawline contour, mild downshifting of subcutaneous volume; score 2: moderate loss of jawline contour, moderate downshifting of subcutaneous volume; score 3: severe loss of jawline contour, severe downshifting of subcutaneous volume, and; score 4: very severe loss of jawline contour, diffuse mandibular angle, very severe downshifting of subcutaneous volume. The GAIS is a 7-point scale, where score ranges from (0-7) as: score 0: very much worse; score 1: much worse; score 3: worse; score 4: no change; score 5: improved; score 6: much improved; score 7: very much improved. An &quot;improvement&quot; on the GAIS for the treating investigator was classified as investigators who rated participants as &quot;improved&quot;, &quot;much improved&quot;, or &quot;very much improved&quot;. All other ratings on the GAIS were classified as &quot;no improvement&quot;.</description>
          <population>The FAS comprised the subset of participants in the randomized set for whom the primary efficacy variable was available. The GAIS was assessed only in treated subjects (i.e., not in Control Group: Untreated); therefore, the analysis is on observed cases, where data were available for both assessments.</population>
          <units>percentage of jawlines</units>
          <param>Number</param>
          <units_analyzed>Jawlines</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Jawlines</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GAIS improvement and MJAS ≥ 1-grade improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iGAIS improvement and MJAS no improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iGAIS no improvement and MJAS ≥ 1-grade improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iGAIS no improvement and MJAS no improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 4</time_frame>
      <desc>The investigator asked the participant for adverse events (AEs) systematically at each visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group: Radiesse (+) Injectable Implant</title>
          <description>Participants received Radiesse+Lidocaine Injectable Implant up to 3.0cc volume, once within the jawline region of anterior to posterior boundaries (from the mentum to the earlobe) and superior to inferior boundaries (from the lower cheek to the lower body of the jawline).</description>
        </group>
        <group group_id="E2">
          <title>Control Group: Untreated</title>
          <description>Participants did not receive jawline treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Disclosure Manager</name_or_title>
      <organization>Merz Pharmaceuticals GmbH</organization>
      <phone>+49 69 1503 1</phone>
      <email>clinicaltrials@merz.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

